Comprehensive Portfolio Management LLC Lowers Holdings in Gilead Sciences, Inc. (GILD)

Comprehensive Portfolio Management LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,626 shares of the biopharmaceutical company’s stock after selling 340 shares during the quarter. Comprehensive Portfolio Management LLC’s holdings in Gilead Sciences were worth $301,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of GILD. Athena Capital Advisors LLC bought a new position in Gilead Sciences in the fourth quarter valued at approximately $27,000. Capital Financial Planning LLC bought a new position in Gilead Sciences in the fourth quarter valued at approximately $27,000. Advisors Preferred LLC bought a new position in Gilead Sciences in the fourth quarter valued at approximately $31,000. Legacy Financial Advisors Inc. lifted its stake in Gilead Sciences by 361.3% in the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 383 shares in the last quarter. Finally, Claybrook Capital LLC bought a new position in Gilead Sciences in the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 80.20% of the company’s stock.

In other news, Director Gayle E. Wilson sold 19,068 shares of the business’s stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total value of $1,279,081.44. Following the completion of the sale, the director now owns 143,567 shares of the company’s stock, valued at $9,630,474.36. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John Francis Cogan sold 2,700 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $65.07, for a total transaction of $175,689.00. Following the completion of the sale, the director now directly owns 57,560 shares of the company’s stock, valued at approximately $3,745,429.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,402 shares of company stock worth $2,613,954. Corporate insiders own 0.20% of the company’s stock.

NASDAQ:GILD opened at $64.54 on Wednesday. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $79.61. The firm has a market capitalization of $83.46 billion, a price-to-earnings ratio of 10.49, a P/E/G ratio of 4.12 and a beta of 1.16. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.30 and a current ratio of 3.38.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the prior year, the firm earned $1.78 earnings per share. Gilead Sciences’s revenue for the quarter was down 2.6% on a year-over-year basis. On average, analysts predict that Gilead Sciences, Inc. will post 6.23 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a $0.63 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 annualized dividend and a dividend yield of 3.90%. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s payout ratio is currently 40.98%.

A number of research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, January 23rd. Mizuho reiterated a “buy” rating and issued a $88.00 price objective on shares of Gilead Sciences in a report on Tuesday, February 26th. Citigroup reiterated a “buy” rating and issued a $100.00 price objective on shares of Gilead Sciences in a report on Tuesday, February 5th. Maxim Group reiterated a “buy” rating and issued a $84.00 price objective on shares of Gilead Sciences in a report on Friday, March 29th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Gilead Sciences in a report on Thursday, March 7th. One analyst has rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $82.00.

TRADEMARK VIOLATION NOTICE: “Comprehensive Portfolio Management LLC Lowers Holdings in Gilead Sciences, Inc. (GILD)” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://sportsperspectives.com/2019/04/17/comprehensive-portfolio-management-llc-lowers-holdings-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Recommended Story: Catch-Up Contributions

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.